Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9

Genes, Chromosomes & Cancer
Audrey SindtEric Delabesse

Abstract

The t(9;22)(q34;q11) translocation occurs in chronic myeloid leukemia (CML) and adult B-cell acute lymphoblastic leukemia (ALL), leading to fusion of BCR to ABL1 and constitutive activation of ABL1 tyrosine kinase activity. The main BCR-ABL1 breakpoints result in P190 BCR-ABL1 or P210 BCR-ABL1 fusion proteins. The latter is found in almost all cases of CML and in one third of the cases of t(9;22)-positive adult B-ALL. P190 BCR-ABL1 is found in the remaining two thirds of t(9;22)-positive adult B-ALL cases but only exceptionally in CML. We describe here the first case of t(9;22)(q34;q11) associated with t(10;11)(p13;q14) in acute monocytic leukemia. The recurrent t(10;11)(p13;q14) translocation, usually found in acute myeloid leukemia (AML) and T-ALL, merges PICALM to MLLT10. RT-PCR enabled identification of PICALM-MLLT10 and BCR-ABL1 e1-a2 fusion transcripts; in the context of chronic and acute myeloid leukemia, the latter usually has a monocytic presentation. We also identified overexpression of HOXA9, a gene essential to myeloid differentiation that is expressed in PICALM-MLLT10 and MLL-rearranged acute leukemias. This case fits with and extends a recently proposed multistage AML model in which constitutive activation of tyro...Continue Reading

References

Oct 1, 1992·Cancer Genetics and Cytogenetics·N DastugueP Colombies
Oct 10, 1995·Proceedings of the National Academy of Sciences of the United States of America·V SahaB D Young
May 14, 1996·Proceedings of the National Academy of Sciences of the United States of America·M H DreylingS K Bohlander
Mar 10, 2001·Genes, Chromosomes & Cancer·H G AhujaM L Slovak
Dec 4, 2001·Nature Genetics·Scott A ArmstrongStanley J Korsmeyer
Mar 12, 2002·British Journal of Haematology·G DamajB Varet
May 29, 2002·Proceedings of the National Academy of Sciences of the United States of America·Ajeeta B DashD Gary Gilliland
Jun 13, 2002·Proceedings of the National Academy of Sciences of the United States of America·Louise M KellyD Gary Gilliland
Aug 27, 2002·Annual Review of Genomics and Human Genetics·Louise M Kelly, D Gary Gilliland
Oct 3, 2002·Nature Reviews. Cancer·Cory Abate-Shen
Nov 26, 2002·Seminars in Hematology·D Gary Gilliland
Jun 5, 2003·Proceedings of the National Academy of Sciences of the United States of America·T RozovskaiaE Canaani
Mar 23, 2004·Annual Review of Immunology·Stephane Wong, Owen N Witte
Jan 15, 2005·Proceedings of the National Academy of Sciences of the United States of America·Yue-Ying WangSai-Juan Chen
Apr 9, 2005·International Journal of Hematology·Katsuro ItoMasami Bessho
Apr 27, 2005·Cell·Yuki OkadaYi Zhang
Jul 19, 2005·The Journal of Clinical Investigation·Christina SchesslChristian Buske

❮ Previous
Next ❯

Citations

Feb 25, 2014·Future Oncology·Etienne De BraekeleerMarc De Braekeleer
Jun 15, 2016·Annals of Hematology·Nina Rosa NeuendorffJörg Westermann
Oct 4, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Claudia GemelliSergio Ferrari

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.